Teduglutide for treatment of adult patients with short bowel syndrome

References

• Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015 apr;34(2):171‑80.
   PubMed Web of Science ®Google Scholar
• Shaffer J. Definition and service development. Clin Nutr. 2002 aug;21:144‑5.
   PubMedGoogle Scholar
• Orphanet [Internet]. Available from: http://www.orpha.net/consor/cgi-bin/index.php?lng=FR
   Google Scholar
• Pironi L, Hébuterne X, Van Gossum A, et al. Candidates for intestinal transplantation: a multicenter survey in Europe. Am J Gastroenterol. 2006 jul;101(7):1633–1643. quiz 1679.
   PubMed Web of Science ®Google Scholar
• Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016 apr;35(2):247–307.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB. Short bowel syndrome – characterisation of an orphan condition with many phenotypes. Expert Opin Orphan Drugs. 2013 jul;1(7):515–525.
   Web of Science ®Google Scholar
• Tappenden KA. Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy. JPEN J Parenter Enteral Nutr. 2014 may;38(1 Suppl):14S–22S.
   PubMed Web of Science ®Google Scholar
• Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology. 1999 nov;117(5):1043–1050.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014 may;38(1 Suppl):45S–52S.
   PubMedGoogle Scholar
• Pape U-F, Maasberg S, Pascher A. Pharmacological strategies to enhance adaptation in intestinal failure. Curr Opin Organ Transplant. 2016 apr;21(2):147–152.
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr. 1994 feb;18(1):26–34.
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Haymond MW, Bennet WM, et al. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology. 1994 aug;107(2):379–388.
   PubMed Web of Science ®Google Scholar
• Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr. 1995 aug;19(4):296–302.
   PubMed Web of Science ®Google Scholar
• Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg. 2005 nov;242(5):655–661.
   PubMed Web of Science ®Google Scholar
• Wales PW, Nasr A, De Silva N, et al. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev. 2010 jun;16(6):CD006321.
   Google Scholar
• Seguy D, Darmaun D, Duhamel A, et al. Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study. Am J Clin Nutr. 2014 sept;100(3):850–858.
   PubMed Web of Science ®Google Scholar
• Vipperla K, O’Keefe SJ. Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block. Clin Exp Gastroenterol. 2014 dec;7:489–495.
   PubMedGoogle Scholar
• Pironi L, Paganelli F, Labate AMM, et al. Safety and efficacy of home parenteral nutrition for chronic intestinal failure: a 16-year experience at a single centre. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2003 may;35(5):314–324.
   Google Scholar
• Lloyd DAJ, Vega R, Bassett P, et al. Survival and dependence on home parenteral nutrition: experience over a 25‐year period in a UK referral centre. Aliment Pharmacol Ther. 2006 oct;24(8):1231–1240.
   PubMed Web of Science ®Google Scholar
• Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. Hepatol Baltim Md. 2006 jan;43(1):9–19.
   PubMed Web of Science ®Google Scholar
• Howard L, Ashley C. Management of complications in patients receiving home parenteral nutrition. Gastroenterology. 2003 may;124(6):1651–1661.
   PubMed Web of Science ®Google Scholar
• Amiot A, Messing B, Corcos O, et al. Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. Clin Nutr Edinb Scotl. 2013 jun;32(3):368‑74.
   Google Scholar
• Grant D, Abu-Elmagd K, Mazariegos G, et al. Intestinal transplant registry report: global activity and trends. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2015 jan;15(1):210–219.
   PubMed Web of Science ®Google Scholar
• Pironi L, Joly F, Forbes A, et al. Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut. 2011 jan;60(1):17–25.
   PubMed Web of Science ®Google Scholar
• Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support for energy absorption as small-bowel failure proceeds. Am J Clin Nutr. 1996 aug;64(2):222–231.
   PubMed Web of Science ®Google Scholar
• Crenn P, Morin MC, Joly F, et al. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut. 2004 sept;53(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000 sept;47(3):370–376.
   PubMed Web of Science ®Google Scholar
• Nightingale JM, Kamm MA, Van Der Sijp JR, et al. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the ‘colonic brake’ to gastric emptying. Gut. 1996 aug;39(2):267–272.
   PubMed Web of Science ®Google Scholar
• Gillard L, Billiauws L, Stan-Iuga B, et al. Enhanced ghrelin levels and hypothalamic Orexigenic AgRP and NPY neuropeptide expression in models of jejuno-colonic short bowel syndrome. Sci Rep. 2016;6:28345.
   PubMed Web of Science ®Google Scholar
• Messing B, Pigot F, Rongier M, et al. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology. 1991 jun;100(6):1502–1508.
   PubMed Web of Science ®Google Scholar
• Joly F, Mayeur C, Bruneau A, et al. Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome. Biochimie. 2010 jul;92(7):753–761.
   PubMed Web of Science ®Google Scholar
• Mayeur C, Gratadoux -J-J, Bridonneau C, et al. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. Plos One. 2013 jan;8(1):e54335.
   PubMed Web of Science ®Google Scholar
• Mayeur C, Gillard L, Le Beyec J, et al. Extensive intestinal resection triggers behavioral adaptation, intestinal remodeling and microbiota transition in short bowel syndrome. Microorg. 2016 mar;4(1):16.
   Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001 mar;120(4):806–815.
   PubMed Web of Science ®Google Scholar
• Koopmann MC, Liu X, Boehler CJ, et al. Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. JPEN J Parenter Enteral Nutr. 2009 dec;33(6):629-638-639.
   PubMed Web of Science ®Google Scholar
• Martin G-R, Beck P-L, Sigalet D-L. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol. 2006 jul 14;12(26):4117–4129.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Hansen BS, et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut. 1999 oct;45(4):559–563.
   PubMed Web of Science ®Google Scholar
• Sobrino Crespo C, Perianes Cachero A, Puebla Jiménez L, et al. Peptides and food intake. Front Endocrinol. 2014;5:58.
   PubMed Web of Science ®Google Scholar
• Hsieh J, Longuet C, Maida A, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 2009 sept;137(3):997-1005, 1005-4.
   Web of Science ®Google Scholar
• Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol. 1997 dec;273(6 Pt 2):R1965–1971.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 may;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561–583.
   PubMed Web of Science ®Google Scholar
• Schwartz LK, O’Keefe SJD, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016;7:e142.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996 jul 23;93(15):7911–7916.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Ther Adv Gastroenterol. 2012 may;5(3):159–171.
   PubMed Web of Science ®Google Scholar
• Marier J-F, Mouksassi M-S, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J Clin Pharmacol. 2010 jan;50(1):36–49.
   PubMed Web of Science ®Google Scholar
• Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000 aug;85(8):2884–2888.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005 sept;54(9):1224–1231.
   PubMed Web of Science ®Google Scholar
• Teduglutide – Micromedex [Internet]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evi dencexpert.DoIntegratedSearch#
   Google Scholar
• Pubchem. Teduglutide |C164H252N44O55S - PubChem [Internet]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/16139605#section=Top
   Google Scholar
• Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab. 2007 aug;293(2):E460–E465.
   PubMed Web of Science ®Google Scholar
• Ørskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept. 2005 jan;124(1–3):105–112.
   PubMedGoogle Scholar
• Sigalet DL, Lam V, Boctor D. The assessment, and glucagon-like peptide-2 modulation, of intestinal absorption and function. Semin Pediatr Surg. 2010 feb;19(1):44–49.
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol. 2003 nov;81(11):1005–1012.
   PubMed Web of Science ®Google Scholar
• Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006 jan;130(1):150–164.
   PubMed Web of Science ®Google Scholar
• Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000 jul;47(1):112–119.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Lipari M, Kulik JK, et al. Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother. 2014 may;48(9):1209–1213.
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004 jan;34(1):140–147.
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009 nov;45(5):833–842.
   PubMed Web of Science ®Google Scholar
• Marier J-F, Beliveau M, Mouksassi M-S, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008 nov;48(11):1289–1299.
   PubMed Web of Science ®Google Scholar
• Nave R, Halabi A, Herzog R, et al. Pharmacokinetics of teduglutide in subjects with renal impairment. Eur J Clin Pharmacol. 2013 may;69(5):1149–1155.
   PubMed Web of Science ®Google Scholar
• PROTOCOL CL0600-015. A phase I, randomized, open-label, 3-way crossover bioavailability study of 10 mg teduglutide in healthy adults. 2005.
   Google Scholar
• Résumé des caractéristiques du produit - Revestive[Internet]. Available from: http://ec.europa.eu/health/documents/community-register/2016/20160629135363/anx_135363_fr.pdf
   Google Scholar
• Brubaker PL, Crivici A, Izzo A, et al. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology. 1997 nov;138(11):4837–4843.
   PubMed Web of Science ®Google Scholar
• Nørholk LM, Holst JJ, Jeppesen PB. Treatment of adult short bowel syndrome patients with teduglutide. Expert Opin Pharmacother. 2012 feb;13(2):235–243.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011 jul;60(7):902–914.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 dec;143(6):1473–1481.e3.
   PubMed Web of Science ®Google Scholar
• O’Keefe SJD, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013 jul;11(7):815-823-3.
   Google Scholar
• Limited TPC. Revestive® (teduglutide) receives European marketing authorization for the treatment of adults with Short Bowel Syndrome (SBS) |Takeda Pharmaceutical Company Limited [Internet]. Available from: https://www.takeda.com/news/2012/20120905_3995.html
   Google Scholar
• Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech [Internet]. Available from: https://www.shire.com/newsroom/2015/january/~/media/7ebc9123c56549e3a797af4c34021eab.ashx
   Google Scholar